|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBE2I |
Gene summary for UBE2I |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBE2I | Gene ID | 7329 |
| Gene name | ubiquitin conjugating enzyme E2 I | |
| Gene Alias | C358B7.1 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | A8K503 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7329 | UBE2I | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.84e-06 | 5.23e-01 | -0.0811 |
| 7329 | UBE2I | HTA11_347_2000001011 | Human | Colorectum | AD | 6.72e-03 | 2.98e-01 | -0.1954 |
| 7329 | UBE2I | HTA11_696_2000001011 | Human | Colorectum | AD | 8.80e-04 | 3.84e-01 | -0.1464 |
| 7329 | UBE2I | HTA11_866_2000001011 | Human | Colorectum | AD | 2.58e-03 | 2.96e-01 | -0.1001 |
| 7329 | UBE2I | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.03e-11 | 7.19e-01 | -0.059 |
| 7329 | UBE2I | HTA11_866_3004761011 | Human | Colorectum | AD | 1.23e-07 | 4.67e-01 | 0.096 |
| 7329 | UBE2I | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.77e-11 | 5.65e-01 | 0.0674 |
| 7329 | UBE2I | HTA11_6818_2000001011 | Human | Colorectum | AD | 4.06e-02 | 4.43e-01 | 0.0112 |
| 7329 | UBE2I | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.95e-06 | 5.46e-01 | 0.0588 |
| 7329 | UBE2I | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.08e-08 | 5.66e-01 | 0.294 |
| 7329 | UBE2I | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 4.21e-07 | 1.33e+00 | 0.3487 |
| 7329 | UBE2I | HTA11_99999965104_69814 | Human | Colorectum | MSS | 3.86e-20 | 1.06e+00 | 0.281 |
| 7329 | UBE2I | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.62e-19 | 8.86e-01 | 0.3859 |
| 7329 | UBE2I | HTA11_99999973899_84307 | Human | Colorectum | MSS | 8.18e-06 | 6.51e-01 | 0.2585 |
| 7329 | UBE2I | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.96e-08 | 4.42e-01 | 0.3005 |
| 7329 | UBE2I | A015-C-203 | Human | Colorectum | FAP | 1.47e-04 | -5.40e-03 | -0.1294 |
| 7329 | UBE2I | A002-C-205 | Human | Colorectum | FAP | 9.68e-04 | -6.81e-02 | -0.1236 |
| 7329 | UBE2I | A015-C-006 | Human | Colorectum | FAP | 1.41e-06 | 3.67e-01 | -0.0994 |
| 7329 | UBE2I | A002-C-114 | Human | Colorectum | FAP | 4.36e-03 | 1.31e-01 | -0.1561 |
| 7329 | UBE2I | A015-C-104 | Human | Colorectum | FAP | 8.32e-06 | 4.97e-02 | -0.1899 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007170914 | Thyroid | PTC | membrane assembly | 31/5968 | 50/18723 | 1.12e-05 | 1.23e-04 | 31 |
| GO:00070595 | Thyroid | PTC | chromosome segregation | 146/5968 | 346/18723 | 2.99e-05 | 2.87e-04 | 146 |
| GO:00069977 | Thyroid | PTC | nucleus organization | 65/5968 | 133/18723 | 3.16e-05 | 3.01e-04 | 65 |
| GO:00169256 | Thyroid | PTC | protein sumoylation | 30/5968 | 53/18723 | 1.71e-04 | 1.31e-03 | 30 |
| GO:00717636 | Thyroid | PTC | nuclear membrane organization | 21/5968 | 33/18723 | 1.73e-04 | 1.32e-03 | 21 |
| GO:00069985 | Thyroid | PTC | nuclear envelope organization | 27/5968 | 47/18723 | 2.57e-04 | 1.84e-03 | 27 |
| GO:00482855 | Thyroid | PTC | organelle fission | 188/5968 | 488/18723 | 9.64e-04 | 5.77e-03 | 188 |
| GO:00314685 | Thyroid | PTC | nuclear envelope reassembly | 10/5968 | 14/18723 | 2.77e-03 | 1.38e-02 | 10 |
| GO:00002804 | Thyroid | PTC | nuclear division | 167/5968 | 439/18723 | 3.27e-03 | 1.60e-02 | 167 |
| GO:190332034 | Thyroid | ATC | regulation of protein modification by small protein conjugation or removal | 152/6293 | 242/18723 | 9.76e-21 | 1.71e-18 | 152 |
| GO:014001416 | Thyroid | ATC | mitotic nuclear division | 171/6293 | 287/18723 | 1.13e-19 | 1.66e-17 | 171 |
| GO:000705913 | Thyroid | ATC | chromosome segregation | 183/6293 | 346/18723 | 8.03e-14 | 4.23e-12 | 183 |
| GO:001820516 | Thyroid | ATC | peptidyl-lysine modification | 193/6293 | 376/18723 | 6.92e-13 | 3.06e-11 | 193 |
| GO:004828512 | Thyroid | ATC | organelle fission | 229/6293 | 488/18723 | 4.79e-10 | 1.29e-08 | 229 |
| GO:000028011 | Thyroid | ATC | nuclear division | 207/6293 | 439/18723 | 1.98e-09 | 4.80e-08 | 207 |
| GO:0043123111 | Thyroid | ATC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 97/6293 | 186/18723 | 1.31e-07 | 2.16e-06 | 97 |
| GO:0043122112 | Thyroid | ATC | regulation of I-kappaB kinase/NF-kappaB signaling | 123/6293 | 249/18723 | 1.65e-07 | 2.64e-06 | 123 |
| GO:0007249111 | Thyroid | ATC | I-kappaB kinase/NF-kappaB signaling | 135/6293 | 281/18723 | 3.31e-07 | 4.91e-06 | 135 |
| GO:004409114 | Thyroid | ATC | membrane biogenesis | 34/6293 | 55/18723 | 1.69e-05 | 1.56e-04 | 34 |
| GO:007170915 | Thyroid | ATC | membrane assembly | 31/6293 | 50/18723 | 3.66e-05 | 2.99e-04 | 31 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04120 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
| hsa041201 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
| hsa041204 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
| hsa041205 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
| hsa041206 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
| hsa041207 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
| hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
| hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
| hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
| hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
| hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
| hsa030137 | Esophagus | HGIN | Nucleocytoplasmic transport | 31/1383 | 108/8465 | 8.29e-04 | 7.95e-03 | 6.31e-03 | 31 |
| hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
| hsa0301312 | Esophagus | HGIN | Nucleocytoplasmic transport | 31/1383 | 108/8465 | 8.29e-04 | 7.95e-03 | 6.31e-03 | 31 |
| hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0301321 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
| hsa040645 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
| hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0301331 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
| hsa0406412 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBE2I | SNV | Missense_Mutation | c.309G>C | p.Trp103Cys | p.W103C | P63279 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-C5-A2LX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| UBE2I | SNV | Missense_Mutation | novel | c.117N>A | p.Met39Ile | p.M39I | P63279 | protein_coding | deleterious(0.01) | benign(0.052) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| UBE2I | SNV | Missense_Mutation | c.13N>A | p.Ala5Thr | p.A5T | P63279 | protein_coding | deleterious(0.03) | benign(0.146) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| UBE2I | SNV | Missense_Mutation | novel | c.464N>G | p.Phe155Cys | p.F155C | P63279 | protein_coding | deleterious(0.05) | benign(0.007) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| UBE2I | SNV | Missense_Mutation | novel | c.469C>T | p.Pro157Ser | p.P157S | P63279 | protein_coding | deleterious(0.02) | benign(0) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| UBE2I | SNV | Missense_Mutation | c.247N>A | p.His83Asn | p.H83N | P63279 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| UBE2I | SNV | Missense_Mutation | novel | c.469C>T | p.Pro157Ser | p.P157S | P63279 | protein_coding | deleterious(0.02) | benign(0) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| UBE2I | SNV | Missense_Mutation | novel | c.263N>A | p.Pro88His | p.P88H | P63279 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| UBE2I | SNV | Missense_Mutation | novel | c.181N>T | p.Arg61Trp | p.R61W | P63279 | protein_coding | tolerated(0.07) | probably_damaging(0.98) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| UBE2I | SNV | Missense_Mutation | novel | c.88N>C | p.Lys30Gln | p.K30Q | P63279 | protein_coding | tolerated(0.1) | benign(0.321) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7329 | UBE2I | TRANSCRIPTION FACTOR BINDING, ENZYME | cisplatin | CISPLATIN | 19859084 | |
| 7329 | UBE2I | TRANSCRIPTION FACTOR BINDING, ENZYME | irinotecan | IRINOTECAN | 19859084 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |